Ikeda Y, Oomori H, Koyanagi N, Mori M, Kamakura T, Minagawa S, Tateishi H, Sugimachi K
Department of Surgery II, Faculty of Medicine, Kyushu University, Japan.
Oncology. 1995 Nov-Dec;52(6):483-6. doi: 10.1159/000227515.
Preoperative serum CEA and CA 19-9 levels in 158 patients with gastric cancer were analyzed with respect to prognostic factors, using univariate and multivariate analysis. The incidence of high preoperative levels of both CEA and CA 19-9 was 10.1% (16/158). 13.9% (22/158) showed high CEA levels and normal CA 19-9 levels, whereas the reverse was true in 16.5% (26/158). Neither marker showed a high level in 59.5% (94/158). The multivariate analysis showed that in addition to tumor stage, the depth of invasion, liver metastasis and peritoneal dissemination, combination assays of preoperative serum CEA and CA 19-9 levels were an independent prognostic factor. Combination assays of preoperative serum CEA and CA 19-9 will allow us to conduct a more careful postoperative follow-up of high-risk patients, and also help determine the optimum adjuvant chemotherapy.
对158例胃癌患者术前血清癌胚抗原（CEA）和糖类抗原19-9（CA 19-9）水平进行分析，以探讨其作为预后因素的价值，采用单因素和多因素分析方法。术前CEA和CA 19-9水平均升高的发生率为10.1%（16/158）。13.9%（22/158）患者CEA水平升高而CA 19-9水平正常，反之，16.5%（26/158）患者CA 19-9水平升高而CEA水平正常。59.5%（94/158）患者两种标志物水平均未升高。多因素分析显示，除肿瘤分期、浸润深度、肝转移和腹膜播散外，术前血清CEA和CA 19-9水平联合检测是独立的预后因素。术前血清CEA和CA 19-9水平联合检测有助于对高危患者进行更密切的术后随访，并有助于确定最佳辅助化疗方案。
